Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CE-DBT vs CE-MRI in known breast lesions
NCT05754749Phase 1Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2023
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iohexol in breast cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Reader confidence in identifying lesions on CE-DBT compared to contrast enhanced dynamic breast MRI at 1.5 years. Started Mar 2023; status: terminated.
02
Drugs
iohexol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05754749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05754749.